Skip to main content
. 2018 Dec 14;8(12):e024004. doi: 10.1136/bmjopen-2018-024004

Table 1.

Baseline characteristics of patients

Characteristic ISDM-P group (n=151) Control group (n=128)
Women 67 (44.4) 59 (46.1)
Age, years 59.5 (6.5) 58.7 (7.9)
Duration of diabetes, years* 8.5 (6.5) 7.5 (6.2)
Systolic blood pressure, mm Hg† 140 (15.1) 140 (16.0)
Diastolic blood pressure, mm Hg† 81 (8.9) 84 (8.5)
Body mass index, kg/m2 33.6 (5.3) 31.5 (6.7)
HbA1c, %§ 7.0 (0.7) 7.0 (1.0)
Total cholesterol†, mmol/L 5.2 (1.1) 5.3 (1.1)
High-density lipoprotein, mmol/L 1.3 (0.4) 1.3 (0.4)
Low-density lipoprotein, mmol/L 3.2 (0.9) 3.4 (1.0)
Smoker (%)** 29 (19.2) 18 (14.5)
Diagnosis hypertension (%)† 134 (88.7) 115 (90.6)
Medication for blood pressure control (%) 129 (85.4) 104 (81.3)
Medication for glucose control 124 (82.1) 95 (74.2)
Insulin 36 (23.8) 28 (21.9)
Metformin 111 (73.5) 88 (68.8)
Sulfonylurea 21 (13.9) 10 (7.8)
Other antidiabetic agents 52 (34.4) 40 (31.3)
Statin medication 50 (33.1) 41 (32.0)
Participation in teaching session for hypertension†† (%) 28 (21.1) 11 (10.1)
Graduation
 None 1 (0.7) 1 (0.8)
 Junior high school 29 (19.2) 24 (18.8)
 High school 93 (61.6) 86 (67.2)
 Qualification for technical college or university 28 (18.5) 17 (13.3)

Values are given as patient number (percentage) or as means (SD).

*ISDM-P n=151, control group n=125.

†ISDM-P n=151, control group n=127.

‡ISDM-P n=150, control group n=126.

§ISDM-P n=151, control group n=128.

¶ISDM-P n=150, control group n=117.

**ISDM-P n=151, control group n=124.

††Patients with diagnosis of hypertension, ISDM-P n=133, control group n=109.

HbA1c, glycated haemoglobin; ISDM-P, informed shared decision-making programme.